Extended Data Fig. 8: Survival in response to combinational therapy of sotiga/nivo/chemo may be affected by regulatory B cells in circulation. | Nature Medicine

Extended Data Fig. 8: Survival in response to combinational therapy of sotiga/nivo/chemo may be affected by regulatory B cells in circulation.

From: Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial

Extended Data Fig. 8

a, KM curves for overall survival stratified by CCR7+ CD11b+ CD27- B cells above and below the median frequency value. b, Heatmap of relative median signal intensity of different proteins present on CCR7+ CD11b+ CD27- B cells on-treatment (C1D15) across all patients. c, Frequencies of CCR7+ CD11b+ CD27- B cells pretreatment (C1D1) and on-treatment (C1D15, C2D1, C4D1), grouped by survival status at 1 year, for each treatment arm. For all cell populations shown, frequencies are out of total leukocytes. On KM curves, median values were determined using all data across the 3 arms, P-values are from a log-rank test between groups, and shaded regions illustrate 95% CI. Box plots show median and quartiles and whiskers depict 95% CI. Individual patient values are shown in thin lines and colored by survival status at 1 year. P-values for timeseries represent two-sided Wilcoxon signed-rank tests between survival groups at each timepoint. Sample sizes for cell populations shown (c): n = 25, 20, 23, 13; n = 29, 23, 24, 22; n = 26, 20, 26, 13 biologically independent samples at C1D1, C1D15, C2D1 and C4D1 in nivo/chemo, sotiga/chemo, sotiga/nivo/chemo treatment arms, respectively.

Back to article page